

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca</u> and according to acceptable standards of care

## **PROTOCOL CODE: SCICANS**

(Page 1 of 2)

Weight:

UC:

### **DOCTOR'S ORDERS**

# REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form DATE: Treatment Date:

Clinical symptoms indicative of immune effector cell-associated neurotoxicity syndrome (ICANS) are headache, confusion, disorientation, speech disturbances, altered levels of consciousness, seizures and motor weakness. Symptoms may also include, but are not limited to: lethargy, aphasia, difficulty concentrating, agitation, tremor, and rarely cerebral edema.

#### Patients must be closely monitored for early signs and symptoms indicative of ICANS.

#### Page the admitting or covering physician at the first signs of ICANS.

Agent administered:	Time of administration:
Admitting Physician: Dr	Contact Number:
Daytime Covering Physician: Dr.	Contact Number:
Overnight Covering Physician: Dr.	Contact Number:

#### **ICANS Management**

#### All Grades:

- Immediately stop administration of treatment medication
- Page the admitting physician or covering physician if not already done
- Admit the patient for further monitoring if not already admitted
- Perform bedside fundoscopic evaluation
- Consider Neurology consultation
- Monitor for seizure activity
- Monitor ability to safely swallow convert medications to IV if impaired
- Avoid medications that cause CNS depression
- Elevate head of bed 30 degrees
- Point of care glucometer testing every 6 hours
- Neurovitals and ICANS assessment, including vital signs, Glasgow coma scale, pupil size for left and right eye and ICE score, Q8H or more frequently if necessary, using Tables 1 and 2 in protocol.
- Monitor vitals Q4H for development of concurrent CRS.
- If concurrent CRS, consider tocilizumab. See <u>SCCRS</u> protocol.

#### Draw the following labs:

CBC & Diff, sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphorus, uric acid, albumin	
creatinine, ALT, alkaline phosphatase, LDH, total bilirubin, lactate, CRP, ferritin, INR, PTT, fibrinogen Other	
labs:	

Repeat above labs Q4H and prior to discharge (if any abnormalities)

Chest x-ray	
Urinalysis with culture	
Blood cultures	
CT head	
MRI head	
LORazepam 1 mg IV Q5mins PRN for seizures, to a maximum of 4mg	
☐ NPO, meds with sips	
DOCTOR'S SIGNATURE:	SIGNATURE:



.

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca</u> and according to acceptable standards of care

## **PROTOCOL CODE: SCICANS**

(Page 2 of 2)

DATE:		
ICANS Management, continued:		
<u>Grade 1</u> :		
If required:		
☐ dexamethasone 10 mg IV ☐ Repeat Q6H		
Grade 2:		
dexamethasone 10 mg IV every 6 hours		
until ICANS Grade 1 or less, then taper over 3 to 7 days (order for taper to be written separately)		
If required, seizure prophylaxis:		
IevETIRAcetam 1500 mg PO load, then IevETIRAcetam 750 mg PO BID*		
*Refer to Protocol for suggested ongoing management of levETIRAcetam.		
Grade 3 and Grade 4:		
Admit the patient urgently to highest level of care. Contact ICU to discuss admission.		
Steroid (select one):		
☐ dexamethasone 10 mg Ⅳ Q6H		
☐ dexamethasone 20 mg Ⅳ Q6H		
methylPREDNISolone 1 g IV daily		
until ICANS is Grade 1 or less, then taper over 3 to 7 days (order for taper to be written separately)		
<b>levETIRAcetam 1500 mg</b> PO, then <b>750 mg</b> PO BID* *Refer to Protocol for suggested ongoing management of levETIRAcetam.		
If required:		
anakinra 100 mg IV in NS 50 mL over 10 mins Q12H		
Or dose modification (for dose escalation or dose reduction if required i.e., for renal impairment):		
☐ anakinra mg IV QH		
DOCTOR'S SIGNATURE:	SIGNATURE:	
	UC:	